[Correspondence] Body-mass index and metastatic melanoma outcomes

We read with great interest the study conducted by Jennifer McQuade and colleagues1 reporting obesity (BMI >30 kg/m2) is associated with improved progression-free survival and overall survival in male patients with metastatic melanoma treated with targeted and immune therapies, and that this effect was not observed in women.1 However, we would query if features of body composition could better explain this observation than BMI. Although BMI is a simple, easy and readily available measure in clinical practice, it is flawed by its inability to differentiate between muscle and adipose tissue.

https://ift.tt/2FhkJrH